Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars – ResearchAndMarkets.com

Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars – ResearchAndMarkets.com




Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships” report has been added to ResearchAndMarkets.com’s offering.

The HER2 receptor is a well characterized biomarker that is overexpressed in a number of types of cancer cells, including 25% to 30% of breast cancers. Trastuzumab, a humanized monoclonal antibody, was designed to bind to the extracellular domain of HER2, and thereby, inhibit the proliferation of tumor cells that overexpress this particular antigen. It was discovered and developed by scientists at Genentech (a fully own subsidiary of Roche), in collaboration with the University of California, Los Angeles; the first clinical trial of the drug was initiated in 1992. In 1998, it was approved after being fast tracked by the FDA; it was marketed under the brand name Herceptin.

Over time, studies have demonstrated that intravenously administered trastuzumab is an effective single-agent immunotherapeutic intervention against a variety of cancers. Moreover, in combination with certain other chemotherapies (such as paclitaxel), the drug has been shown to significantly improve the median time to disease progression and survival time in patients suffering from metastatic breast cancer (characterized by the overexpression of the HER2 receptor).

It is worth mentioning that trastuzumab is also available in three different forms, namely trastuzumab and hyaluronidase-oysk, pertuzumab, trastuzumab, and hyaluronidase-zzxf, and ado-trastuzumab emtansine (an antibody drug conjugate). Considering the opportunity associated with this product, its corresponding biosimilar developer landscape is also vast. With multiple enemy products already in the market, and several others under development, the trastuzumab biosimilars market is anticipated to witness noteworthy growth in the short-mid term.

The report features an extensive study of the current developer landscape and clinical research scenario related to all the follow-on products of the blockbuster biologic drug, Herceptin, which are either available or under development. The information in this report has been presented across two deliverables, namely an Excel sheet, featuring an interactive dashboard, and a PowerPoint presentation, summarizing the ongoing activity in this domain, and key insights drawn from the available data.

The report features the following details:

  • Detailed review of the trastuzumab biosimilars pipeline and affiliated developer landscape, featuring a list of involved innovator companies and their respective therapy candidates. It includes insights based on the current status of biosimilar candidates, and important developer related details (including headquarters, and type of developer).
  • An analysis of the various trastuzumab biosimilar candidates that have either been approved and/or launched across developed and developing markets, worldwide. The insights presented in this section are based on a number of relevant parameters, such as current status, year of approval/launch, and geographies where the product has been approved/launched.
  • An assessment of the trastuzumab biosimilars that are under development, featuring details such as current phase of development and geographical locations where clinical/preclinical research is underway. In addition to the molecules that are in the pipeline, the report also features information on research grade products and inactive, terminated and withdrawn product development programs.
  • An analysis of the various partnerships related to trastuzumab biosimilars, based on parameters, such as year of partnership, type of partnership, and geographical locations of partnering entities.
  • A detailed assessment of the various marketing and distribution agreements inked in relation to Herceptin biosimilars, highlighting the key players involved.

For more information about this report visit https://www.researchandmarkets.com/r/jc04m7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900